


英文名 | JNJ-42226314 | ||
级别 | For Signal Pathway Regulation | 相关类别 | 其他 |
储存 | 冷冻(-20℃) | 分子量 | 489.56 |
靶点 | Others | ||
编 号 | 包装 | 库存 | 目录价(¥) | 您的价格(¥) | 数 量 |
A429197-0001 | 1 MG | 咨询 |
![]() |
![]() |
![]() |
A429197-0005 | 5 MG | 咨询 |
![]() |
![]() |
![]() |
A429197-0010 | 10 MG | 咨询 |
![]() |
![]() |
![]() |
A429197-0025 | 25 MG | 咨询 |
![]() |
![]() |
![]() |
A429197-0050 | 50 MG | 咨询 |
![]() |
![]() |
![]() |
A429197-0100 | 100 MG | 咨询 |
![]() |
![]() |
![]() |
A429197-0500 | 500 MG | 咨询 |
![]() |
![]() |
![]() |
概述
JNJ-42226314 is a competitive, highly selective, and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. It exhibits dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) and demonstrates efficacy in models of neuropathic and inflammatory pain.
属性
保存温度&条件 | 低温;粉末:-20°C,2年;在溶剂中:-80°C,1年 |
信号通路 | 其他 |